SYDNEY, Australia – 3 June 2019 – Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of synthetic antibiotics, today announced the formation of a Clinical Advisory Committee to assist in the Board’s growing clinical considerations under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).
The new Clinical Advisory Committee will be chaired by Dr David Bowers, Spinal Injury Physician at Royal North Shore and other University Hospitals in Sydney.
Dr Bowers has a specialist interest in the treatment of complex and life-threatening antibiotic resistant infections, particularly among patients with severe spinal cord injuries.
Recce Pharmaceuticals Executive Chairman Dr Graham Melrose said, “Dr Bowers experience will significantly enhance the insights we receive from the new committee as we advance our new antibiotic product pipeline into the clinic.”
Independent to the Company, Dr Bowers has not accepted any remuneration for his valued contributions to date and will continue on this basis in the now formalised role.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.
Issued for and on behalf of Recce by Instinctif Partners.
For more information please contact firstname.lastname@example.org